Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Lung Neoplasms 3Rectal Neoplasms 2Prostatic Neoplasms 2Smoking Cessation 1Motor Activity 1Inflammation 1Fatigue 1Endometrial Neoplasms 1Colonic Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Oxaliplatin 146Fluorouracil 137Capecitabine 121Leucovorin 106Irinotecan 85Radiotherapy 66Bevacizumab 64Cetuximab 46Folfox protocol 27Surgical Procedures, Operative 23Radiation 23Drug Therapy 22Panitumumab 19XELOX 18Chemotherapy, Adjuvant 15Neoadjuvant Therapy 14Radiotherapy, Intensity-Modulated 13Chemoradiotherapy 13Magnetic Resonance Spectroscopy 11regorafenib 10Nivolumab 10Floxuridine 10sintilimab 8raltitrexed 8Specimen Handling 8IFL protocol 8Celecoxib 8Biopsy 8trifluridine tipiracil drug combination 7tislelizumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Rectal Neoplasms × Hematologic Tests × Clear all
NCT02288078 2014-11-13

Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402)

Clinical Research Support Center Kyush

Phase 2 Unknown
74 enrolled
Gastrointestinal

Fatigue, Rectal Neoplasms

NCT02280070 2014-10-31

RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301).

Clinical Research Support Center Kyush

Phase 2 Unknown
110 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡